Coloplast AS (COLO B):企業の財務・戦略的SWOT分析

◆英語タイトル:Coloplast AS (COLO B) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME529FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年2月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥35,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥53,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Coloplast AS (COLO B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Coloplast A/S (Coloplast) manufactures and sells products and offers services for ostomy care, urology care, continence care, and skin and wound care. Its major products include urisheaths; ostomy bags; urine bags; catheters; anal irrigation systems; sling products; advanced foam dressings and hydrocolloid dressings for protection of skin and pressure injuries; cleansers; moisturizers; skin protectants; anti-fungals; and hand cleansers. The company offers its products under brands including SenSura, SpeediCath, Persiteen, Biatain, Conveen, InterDry, Brava and Comfeel. Coloplast supplies its products through subsidiaries and distributors to hospitals, institutions, wholesalers and retailers in Europe, Africa, South America, Asia, Russia, Australia and North America. Coloplast is headquartered in Humlebaek, Denmark.

Coloplast AS Key Recent Developments

Nov 04,2020: Coloplast acquires tibial nerve stimulation developer Nine Continents
Nov 03,2020: Coloplast acquires Nine Continents Medical
Nov 03,2020: Coloplast – Announcement no. 10/2020 – Full-year financial results 2019/20
Nov 03,2020: Coloplast delivers solid full year results despite the COVID-19 pandemic and expects 7-8% organic growth and 31-32% EBIT margin for 2020/21
Nov 03,2020: Coloplast – Announcement no. 11/2020 – Annual Report 2019/20 & Remuneration Report 2019/20

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Coloplast A/S – Key Facts
Coloplast A/S – Key Employees
Coloplast A/S – Key Employee Biographies
Coloplast A/S – Major Products and Services
Coloplast A/S – History
Coloplast A/S – Company Statement
Coloplast A/S – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Coloplast A/S – Business Description
Business Segment: Chronic Care
Overview
Performance
Business Segment: Interventional Urology
Overview
Performance
Business Segment: Wound & Skin Care
Overview
Performance
Geographical Segment: Emerging Markets
Performance
Geographical Segment: European Markets
Target Markets
Performance
Geographical Segment: Other Developed Markets
Target Markets
Performance
R&D Overview
Coloplast A/S – Corporate Strategy
Coloplast A/S – SWOT Analysis
SWOT Analysis – Overview
Coloplast A/S – Strengths
Coloplast A/S – Weaknesses
Coloplast A/S – Opportunities
Coloplast A/S – Threats
Coloplast A/S – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Coloplast A/S, Medical Equipment, Deals By Year, 2015 to YTD 2021
Coloplast A/S, Medical Equipment, Deals By Type, 2015 to YTD 2021
Coloplast A/S, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 04, 2020: Coloplast acquires tibial nerve stimulation developer Nine Continents
Nov 03, 2020: Coloplast – Announcement no. 10/2020 – Full-year financial results 2019/20
Nov 03, 2020: Coloplast delivers solid full year results despite the COVID-19 pandemic and expects 7-8% organic growth and 31-32% EBIT margin for 2020/21
Nov 03, 2020: Coloplast – Announcement no. 11/2020 – Annual Report 2019/20 & Remuneration Report 2019/20
Sep 29, 2020: Coloplast launches new 2025 strategy and provides new long-term financial guidance
Aug 18, 2020: Coloplast reports -2% organic growth in Q3 due to significant negative impact from COVID-19 – and 5% year to date organic growth
Aug 18, 2020: Coloplast strengthens Executive Management
May 06, 2020: Coloplast: Interim Financial Report, H1 2019/20
May 06, 2020: Coloplast continues solid performance in Q2 with 9% organic growth
Feb 21, 2020: Coloplast – Announcement no. 2/2020 – share buyback programme
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Coloplast A/S, Key Facts
Coloplast A/S, Key Employees
Coloplast A/S, Key Employee Biographies
Coloplast A/S, Major Products and Services
Coloplast A/S, History
Coloplast A/S, Other Locations
Coloplast A/S, Subsidiaries
Coloplast A/S, Key Competitors
Coloplast A/S, Ratios based on current share price
Coloplast A/S, Annual Ratios
Coloplast A/S, Annual Ratios (Cont...1)
Coloplast A/S, Annual Ratios (Cont...2)
Coloplast A/S, Interim Ratios
Coloplast A/S, Medical Equipment, Deals By Year, 2015 to YTD 2021
Coloplast A/S, Medical Equipment, Deals By Type, 2015 to YTD 2021
Coloplast A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Coloplast AS (COLO B):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Drugs for Neglected Diseases initiative:製薬・医療:M&Aディール及び事業提携情報
    Summary Drugs for Neglected Diseases initiative (DNDi) is a non-profit drug research and development (R&D) organization which discovers and develops new drugs for neglected diseases. The organization develops therapeutics for the treatment of various diseases such as human African trypanosomiasis (H …
  • Fortum Corp (FORTUM):石油・ガス:M&Aディール及び事業提携情報
    Summary Fortum Corp (Fortum) is a clean energy company, which generates, distributes and sells heat and electricity. The company undertakes operation and maintenance of power plants; and offers energy-related services. Fortum's operational assets include hydropower plants, condensing power plants, w …
  • F. Hoffmann-La Roche Ltd:戦略・SWOT・企業財務分析
    F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report Summary F. Hoffmann-La Roche Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cross Timbers Royalty Trust (CRT):企業の財務・戦略的SWOT分析
    Summary Cross Timbers Royalty Trust (Cross Timbers Royalty), a subsidiary of Exxon Mobil Corp is an oil and gas company that operates oil fields. It collects and distributes monthly net profits income from overriding interests to unit holders. It also establishes cash reserves for contingencies. Cro …
  • TrustPower Limited:企業の戦略・SWOT・財務分析
    TrustPower Limited - Strategy, SWOT and Corporate Finance Report Summary TrustPower Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Medical Research Council-製薬・医療分野:企業M&A・提携分析
    Summary Medical Research Council (MRC) is a human health research council that offers medical research programs. The council offers research across medical sciences services, universities and hospitals, centers and institutes. It provides data management, research platform, tools and facilities to g …
  • Botswana Power Corp:企業の戦略的SWOT分析
    Botswana Power Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • ROSEN Swiss AG:企業の戦略的SWOT分析
    ROSEN Swiss AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Pilgrim’s Pride Corporation (PPC):企業の財務・戦略的SWOT分析
    Pilgrim's Pride Corporation (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • MorphoSys AG (MOR):企業の財務・戦略的SWOT分析
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, and research applications. The company’s pipeline products include MOR208, MOR103, MOR202, MAA868, VAY736, MOR106, and MOR107. Its drugs are used for the treatment of various types of cancers, psoriasis, rheuma …
  • Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析
    Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • GlaxoSmithKline Plc:企業のM&A・事業提携・投資動向
    GlaxoSmithKline Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GlaxoSmithKline Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Histogenics Corp (HSGX):医療機器:M&Aディール及び事業提携情報
    Summary Histogenics Corp (Histogenics) is a regenerative medicine company that develops, markets and commercializes products for musculoskeletal disorders. The company provides product such as neocart, a tissue implant produced using a patient’s own cartilage cells which are harvested from non-weigh …
  • EQT Corporation (EQT):石油・ガス:M&Aディール及び事業提携情報
    Summary EQT Corp (EQT) is an integrated oil and gas company. It operates production fields in Marcellus, Upper Devonian, Ohio Utica and other plays in Appalachian Basin. The company produces and markets natural gas, natural gas liquids (NGL), ethane and crude oil. EQT provides gathering, transmissio …
  • Voya Financial Inc:企業の戦略・SWOT・財務分析
    Voya Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Voya Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • N4 Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary N4 Pharma Ltd (n4 Pharma), a subsidiary of N4 Pharma Plc, is a drug reformulation company. The company develops and out licensing of new versions of existing high value drugs with an unmet commercial or medical need. Its proprietary platform technology, Cocrys and Nuvac, focus on improving t …
  • Aksigorta A.S. (AKGRT):企業の財務・戦略的SWOT分析
    Aksigorta A.S. (AKGRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Lockheed Martin Aeronautics Company:企業の戦略・SWOT・財務分析
    Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report Summary Lockheed Martin Aeronautics Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • NBE-Therapeutics AG:製薬・医療:M&Aディール及び事業提携情報
    Summary NBE-Therapeutics AG (NBE-Therapeutics) is a biotechnology company that focuses on the development of antibody drug conjugates (ADC) to improve the treatment of cancer. ADCs act against cancer cells via tumor-specific antibodies and deliver powerful cellular toxins to such cancer cells. The c …
  • Quidel Corp (QDEL):医療機器:M&Aディール及び事業提携情報
    Summary Quidel Corp (Quidel) develops, manufactures and markets rapid diagnostic testing solutions for the detection and diagnosis of critical diseases and other medical conditions. Its major products include immunoassays; molecular assays; virology products including traditional cell lines, specime …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆